1245014-75-8

Upstream product

• 50824-04-9 4-bromo-2-(trifluoromethyl)phenol 
• 586-95-8 pyridine-4-methanol 
• 1245014-56-5 4-((4-bromo-2-(trifluoromethyl)phenoxy)methyl)pyridine 
• 73183-34-3 bis(pinacol)diborane 

Downstream Products

• 1245013-76-6 C₂₁H₁₄F₃N₅O 
• 1315463-36-5 methyl-6-(4-(1-N-oxy-pyridin-4-ylmethoxy)-3-(trifluoromethyl)phenyl)-1H-[1,2,3]triazolo[4,5-c]pyridine-4-carbonitrile 
• 1315463-34-3 1-methyl-6-(4-(pyridin-4-ylmethoxy)-3-(trifluoromethyl)phenyl)-1H-[1,2,3]triazolo[4,5-c]pyridine-4-carbonitrile 
• 1315465-06-5 3-amino-4-(methylamino)-6-(4-(pyridin-4-ylmethoxy)-3-(trifluoromethyl)-phenyl)picolinonitrile 

Relevant academic research and scientific papers

1H-[1,2,3]TRIAZOLO[4,5-c]PYRIDINE-4-CARBONITRILE DERIVATIVES

The invention relates to 1H-[1,2,3]triazolo[4,5-c]pyridine-4-carbonitrile derived Cathepsin S inhibitors of Formula (I), wherein R1 is H or (C1-3)alkyl; R2 is halogen or (C1-4)alkyl, optionally substituted with one or more halogens; n is 1 -3; X is O or CH2; U, V and W are CH; or one of U, V and W is N; Y is a group capable of interacting with the Sn....S2 substites of the active site of Cathepsin S; or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising the same as well as to the use of these derivatives for the preparation of a medicament for the treatment of cathepsin S related diseases such as atherosclerosis, obesity, inflammation and immune disorders, such as rheumatoid arthritis, psoriasis, cancer, and chronic pain, such as neuropathic pain.